Investment Thesis
Relmada is a pre-profitability biotech company with unsustainable cash burn of $197.1M annually against only $9.8M cash, despite strong 93.7% YoY revenue growth. While the balance sheet shows strength with minimal debt and high liquidity, the company lacks a clear path to profitability with negative gross margins and operating margins exceeding -370%, making near-term financial viability questionable.
Strengths
- Revenue growth of 93.7% YoY demonstrates market traction and demand
- Fortress balance sheet with zero long-term debt and $218.7M stockholders equity
- High liquidity ratios (18.26x current ratio) providing financial flexibility
- Improving diluted EPS by 45.3% YoY shows operational efficiency gains despite losses
- Large asset base of $235.4M supporting R&D and development activities
Risks
- Catastrophic cash burn of $197.1M annually is unsustainable with only $9.8M cash reserves
- Gross margin of 0.1% indicates severe pricing or cost structure issues preventing profitability
- Operating margin of -377.8% and net margin of -369.8% demonstrate spending far exceeds revenue generation
- Negative ROE (-8.7%) and ROA (-8.1%) destroy shareholder value at current trajectory
- Heavy capital expenditure of $182.1M suggests major investments with execution risk
Key Metrics to Watch
- Operating cash flow trend - must improve from -$15.1M to reach sustainability
- Gross margin expansion - critical to achieving profitability as revenue scales
- Cash runway - monitor remaining months of operations before next financing round required
- Revenue per employee and operating efficiency metrics - track progress toward breakeven
- Capital allocation of $182.1M capex - validate that investments deliver future revenue growth
Financial Metrics
Revenue
5.2M
Net Income
-19.1M
EPS (Diluted)
$-0.22
Free Cash Flow
-197.1M
Total Assets
235.4M
Cash
9.8M
Profitability Ratios
Gross Margin
0.1%
Operating Margin
-377.8%
Net Margin
-369.8%
ROE
-8.7%
ROA
-8.1%
FCF Margin
-3,826.3%
Balance Sheet & Liquidity
Current Ratio
18.26x
Quick Ratio
18.26x
Debt/Equity
0.00x
Debt/Assets
7.1%
Interest Coverage
-6,916.05x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T09:18:03.753527 |
Data as of: 2026-03-31 |
Powered by Claude AI